HERIZON-BTC-01 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

4,984 results for “HERIZON-BTC-01”

Trials

View all 2268 →

Formative Evaluation of The HERizon Project

42 participants · First posted Dec 10, 2020

Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

15 participants · First posted Aug 15, 2019

BTC Neuropsychological Database

First posted Apr 1, 2009

Drugs

View all 1637 →

BTC-86

Investigational

Dental Mesenchymal Pulp Stem Cells

MTC-01

Organizations

View all 160 →

01 Communique Laboratory Inc

Canada

BTC PHARMA PTY LTD

Australia

合肥淡滨尼药业有限公司

News

View all 919 →

Zanidatamab Approved for HER2+ Biliary Tract Cancer

FDA Grants Accelerated Approval to Zanidatamab for HER2-Positive Biliary Tract Cancer

Ziihera (Zanidatamab-hrii) Receives NCCN Recommendation for Biliary Tract Cancers

Page 1 of 499